Braftovi (Encorafenib) + Erbitux (Cetuximab) ± Mektovi (Binimetinib): Market Outlook and Competitive Landscape
Overview of Braftovi + Erbitux ± Mektovi Combination Therapy The combination therapy of Braftovi (encorafenib), Erbitux (cetuximab), and optionally Mektovi (binimetinib) has emerged as a significant treatment option for certain cancers, particularly metastatic colorectal cancer (mCRC) with the BRAFV600E mutation. This targeted approach works by